April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas for the U.S. drug developer's experimental prostate cancer drug, Arvinas said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.9 USD | -1.45% | -8.60% | -22.50% |
Apr. 24 | Arvinas, Inc. Appoints Randy Teel as Chief Business Officer | CI |
Apr. 15 | H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
88.87 CHF | -0.70% | +1.73% | 200B | ||
31.9 USD | -1.45% | -8.60% | 2.21B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.50% | 2.21B | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Novartis licenses Arvinas' cancer drug for up to $1 billion